Want to see BFRI full AI Analyst Report?
BFRI Stock Chart & Stats
$1.09
-$0.01(-0.92%)
At close: 4:00 PM EDT
$1.09
-$0.01(-0.92%)
Day’s Range― - ―
52-Week Range$0.55 - $1.27
Previous CloseN/A
Volume7.39K
Average Volume (3M)249.99K
Market Cap
$14.98M
Enterprise Value$10.85
Total Cash (Recent Filing)$6.32M
Total Debt (Recent Filing)$7.72M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 13, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding12,803,344
10 Day Avg. Volume217,442
30 Day Avg. Volume249,992
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.55
Price to Sales (P/S)0.14
P/FCF Ratio-0.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside450.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$45.65M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsData from the Phase 3 extremities trial and the Phase 2b acne trial expected early in 2026 could validate new indications and materially expand commercial opportunity.
Operational Cost SavingsRestructuring of agreements with former parent Biofrontera AG is expected to deliver cost savings and operational efficiencies that improve margins and cash flow flexibility.
Regulatory FilingA supplemental NDA submission for the extremities indication projected in mid-2026 could enable label expansion and broader prescribing, supporting future revenue growth.
Bears Say
Demand Timing VolatilityCustomer stockpiling ahead of an anticipated price increase could create a pull-forward effect, producing revenue volatility once the stocking period ends.
Profitability PressureA larger-than-planned net loss underscores ongoing profitability challenges that could weigh on the stock until margins show sustained improvement.
Top-line Momentum RiskIn-line quarterly revenue suggests limited top-line momentum, increasing the risk that growth expectations may not be met.
Biofrontera News
BFRI FAQ
What was Biofrontera’s price range in the past 12 months?
Biofrontera lowest stock price was $0.55 and its highest was $1.27 in the past 12 months.
What is Biofrontera’s market cap?
Biofrontera’s market cap is $14.98M.
When is Biofrontera’s upcoming earnings report date?
Biofrontera’s upcoming earnings report date is Aug 13, 2026 which is in 6 days.
How were Biofrontera’s earnings last quarter?
Biofrontera released its earnings results on May 14, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.295.
Is Biofrontera overvalued?
According to Wall Street analysts Biofrontera’s price is currently Undervalued.
Does Biofrontera pay dividends?
Biofrontera does not currently pay dividends.
What is Biofrontera’s EPS estimate?
Biofrontera’s EPS estimate is -0.11.
How many shares outstanding does Biofrontera have?
Biofrontera has 12,803,344 shares outstanding.
What happened to Biofrontera’s price movement after its last earnings report?
Biofrontera reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went up 3.024%.
Which hedge fund is a major shareholder of Biofrontera?
Currently, no hedge funds are holding shares in BFRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofrontera
Biofrontera Inc. (BFRI) is a pharmaceutical company focused on dermatology, primarily commercializing prescription products used in the treatment of skin conditions. The company’s business centers on marketing and selling dermatology therapies in the United States, with a flagship product related to photodynamic therapy for actinic keratoses and field cancerization.
BFRI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a clear, material improvement in core commercial and financial metrics (17% revenue growth, ~16% unit growth, gross margin expansion to ~80%, near-zero operating cash use) alongside meaningful clinical and regulatory progress (sNDA acceptance for sBCC with a PDUFA in September, positive AK Phase III results, encouraging acne data). These positives are tempered by elevated SG&A and operating expenses, ongoing patent/legal costs and a continued going concern qualification with limited liquidity. On balance the transform-driven revenue and margin gains, near-term regulatory catalysts, and improved cash performance materially outweigh the challenges, supporting a constructive view of the company's trajectory while recognizing remaining execution and financing risks.View all BFRI earnings summariesBFRI Stock 12 Month Forecast
Average Price Target
$6.00
▲(450.46% Upside)
Technical Analysis
Ownership Overview
4.37% Insiders
0.90% Mutual Funds
16.24% Other Institutional Investors
77.94% Public Companies and
Individual Investors